Vimarsana
Biggest News Aggregation in the World

Page 7 - Nasdaq Edit News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq Edit. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Edit Today - Breaking & Trending Today

Editas Medicine (NASDAQ:EDIT) Releases Quarterly Earnings Results, Beats Estimates By $0.20 EPS - Vimarsana News

Editas Medicine (NASDAQ:EDIT) Releases Quarterly Earnings Results, Beats Estimates By $0.20 EPS

Editas Medicine (NASDAQ:EDIT – Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.20, Briefing.com reports. The business had revenue of $2.89 million during the quarter, compared to analysts’ expectations of $4.17 million. Editas Medicine had […]

Editas Medicine (NASDAQ:EDIT) Announces Quarterly Earnings Results, Beats Estimates By $0.20 EPS - Vimarsana News

Editas Medicine (NASDAQ:EDIT) Announces Quarterly Earnings Results, Beats Estimates By $0.20 EPS

Editas Medicine (NASDAQ:EDIT – Get Free Report) announced its earnings results on Wednesday. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.20, Briefing.com reports. The firm had revenue of $2.89 million for the quarter, compared to the consensus estimate of $4.17 million. Editas Medicine had a negative net […]

Source: wkrb13.com
Editas Medicine (NASDAQ:EDIT) Posts Quarterly Earnings Results, Beats Expectations By $0.20 EPS - Vimarsana News

Editas Medicine (NASDAQ:EDIT) Posts Quarterly Earnings Results, Beats Expectations By $0.20 EPS

Editas Medicine (NASDAQ:EDIT – Get Free Report) issued its earnings results on Wednesday. The company reported ($0.56) EPS for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.20, Briefing.com reports. Editas Medicine had a negative net margin of 960.70% and a negative return on equity of 56.20%. The business had revenue of $2.89 million […]

Gilmore Neil O'neill Sells 6,486 Shares of Editas Medicine, Inc. (NASDAQ:EDIT) Stock - Vimarsana News

Gilmore Neil O'neill Sells 6,486 Shares of Editas Medicine, Inc. (NASDAQ:EDIT) Stock

Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) CEO Gilmore Neil O’neill sold 6,486 shares of the stock in a transaction that occurred on Monday, June 5th. The stock was sold at an average price of $9.50, for a total value of $61,617.00. Following the sale, the chief executive officer now directly owns 130,169 shares in […]

Editas Medicine, Inc. (NASDAQ:EDIT) Given Consensus Recommendation of "Hold" by Analysts - Vimarsana News

Editas Medicine, Inc. (NASDAQ:EDIT) Given Consensus Recommendation of "Hold" by Analysts

Editas Medicine, Inc. (NASDAQ:EDIT – Get Rating) has been given a consensus rating of “Hold” by the fifteen research firms that are covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation and four have issued a buy recommendation on the company. The […]

Source: wkrb13.com